SanBio Company Limited (4592.T)
JPY 762.0
(-4.87%)
JPY 762.0
(-4.87%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -2.64 Billion JPY | 52.44% |
| 2022 | -5.55 Billion JPY | -18.85% |
| 2021 | -4.67 Billion JPY | -38.16% |
| 2020 | -3.38 Billion JPY | 34.35% |
| 2019 | -5.15 Billion JPY | -76.6% |
| 2018 | -2.92 Billion JPY | 25.88% |
| 2017 | -3.94 Billion JPY | -114.7% |
| 2016 | -1.83 Billion JPY | -85.68% |
| 2015 | -988.39 Million JPY | -156.93% |
| 2014 | 1.73 Billion JPY | 394.55% |
| 2013 | -589.45 Million JPY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -1.16 Billion JPY | -703.78% |
| 2024 Q1 | -144.85 Million JPY | 80.97% |
| 2023 Q4 | -761.28 Million JPY | -696.93% |
| 2023 Q3 | -95.52 Million JPY | 91.77% |
| 2023 Q1 | -626.16 Million JPY | 83.53% |
| 2023 FY | -2.64 Billion JPY | 52.44% |
| 2023 Q2 | -1.16 Billion JPY | -85.47% |
| 2022 Q4 | -3.8 Billion JPY | -1057.61% |
| 2022 Q2 | -1.83 Billion JPY | -482.45% |
| 2022 FY | -5.55 Billion JPY | -18.85% |
| 2022 Q1 | -315.77 Million JPY | 79.79% |
| 2022 Q3 | 396.98 Million JPY | 121.58% |
| 2021 Q4 | -1.56 Billion JPY | -59.19% |
| 2021 FY | -4.67 Billion JPY | -38.16% |
| 2021 Q1 | -860.06 Million JPY | -159.08% |
| 2021 Q2 | -1.27 Billion JPY | -48.12% |
| 2021 Q3 | -981.46 Million JPY | 22.96% |
| 2020 Q2 | -1.7 Billion JPY | -12.82% |
| 2020 Q4 | 1.45 Billion JPY | 189.07% |
| 2020 Q3 | -1.63 Billion JPY | 3.88% |
| 2020 FY | -3.38 Billion JPY | 34.35% |
| 2020 Q1 | -1.5 Billion JPY | 19.7% |
| 2019 FY | -5.15 Billion JPY | -76.6% |
| 2019 Q4 | -1.87 Billion JPY | -52.32% |
| 2019 Q3 | -1.23 Billion JPY | 6.14% |
| 2019 Q2 | -1.31 Billion JPY | -78.32% |
| 2019 Q1 | -736.14 Million JPY | 46.31% |
| 2018 Q4 | -1.37 Billion JPY | -170.07% |
| 2018 Q3 | -507.68 Million JPY | -148.58% |
| 2018 Q2 | -204.23 Million JPY | 75.61% |
| 2018 Q1 | -837.52 Million JPY | -7.19% |
| 2018 FY | -2.92 Billion JPY | 25.88% |
| 2017 Q3 | -882.94 Million JPY | 25.09% |
| 2017 Q1 | -1.09 Billion JPY | -664.59% |
| 2017 FY | -3.94 Billion JPY | -114.7% |
| 2017 Q4 | -781.35 Million JPY | 11.51% |
| 2017 Q2 | -1.17 Billion JPY | -7.42% |
| 2016 Q3 | -546.4 Million JPY | 37.05% |
| 2016 Q4 | -143.51 Million JPY | 73.73% |
| 2016 FY | -1.83 Billion JPY | -85.68% |
| 2016 Q2 | -867.97 Million JPY | -212.89% |
| 2016 Q1 | -277.4 Million JPY | 46.41% |
| 2015 Q3 | -30.8 Million JPY | 90.69% |
| 2015 FY | -988.39 Million JPY | -156.93% |
| 2015 Q1 | -109.07 Million JPY | 38.61% |
| 2015 Q2 | -330.92 Million JPY | -203.39% |
| 2015 Q4 | -517.59 Million JPY | -1580.5% |
| 2014 FY | 1.73 Billion JPY | 394.55% |
| 2014 Q4 | -177.67 Million JPY | 0.0% |
| 2013 FY | -589.45 Million JPY | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 384 Million JPY | 788.542% |
| PRISM BioLab Co.,LTD | -526.91 Million JPY | -401.79% |
| GNI Group Ltd. | 8.09 Billion JPY | 132.665% |
| Linical Co., Ltd. | 338.26 Million JPY | 881.633% |
| Trans Genic Inc. | 4.08 Million JPY | 64824.602% |
| MEDINET Co., Ltd. | -1.43 Billion JPY | -83.873% |
| Soiken Holdings Inc. | -662.2 Million JPY | -299.273% |
| Cytori Cell Research Institute, Inc. | 138.15 Million JPY | 2013.792% |
| AnGes, Inc. | -7.43 Billion JPY | 64.451% |
| OncoTherapy Science, Inc. | -1.28 Billion JPY | -105.258% |
| Nxera Pharma Co., Ltd. | -7.19 Billion JPY | 63.242% |
| Immuno-Biological Laboratories Co., Ltd. | 186.69 Million JPY | 1516.221% |
| NanoCarrier Co., Ltd. | -780 Million JPY | -238.973% |
| Carna Biosciences, Inc. | -1.15 Billion JPY | -129.336% |
| CanBas Co., Ltd. | -1.2 Billion JPY | -118.693% |
| D. Western Therapeutics Institute, Inc. | -812.41 Million JPY | -225.451% |
| RaQualia Pharma Inc. | -323.66 Million JPY | -716.902% |
| Chiome Bioscience Inc. | -1.22 Billion JPY | -116.718% |
| Kidswell Bio Corporation | -1.42 Billion JPY | -85.925% |
| PeptiDream Inc. | 3.03 Billion JPY | 187.093% |
| Oncolys BioPharma Inc. | -1.93 Billion JPY | -36.394% |
| Ribomic Inc. | -1.02 Billion JPY | -158.143% |
| Healios K.K. | -3.82 Billion JPY | 30.84% |
| BrightPath Biotherapeutics Co., Ltd. | -1.16 Billion JPY | -126.354% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -1.48 Billion JPY | -77.497% |
| Delta-Fly Pharma, Inc. | -1.42 Billion JPY | -84.974% |
| StemRIM | -2.02 Billion JPY | -30.762% |
| CellSource Co., Ltd. | 923.14 Million JPY | 386.413% |
| FunPep Company Limited | -933.41 Million JPY | -183.261% |
| Kringle Pharma, Inc. | -854.15 Million JPY | -209.547% |
| Stella Pharma Corporation | -763.74 Million JPY | -246.187% |
| TMS Co., Ltd. | -960.04 Million JPY | -175.405% |
| Noile-Immune Biotech Inc. | -1.13 Billion JPY | -133.979% |
| Cuorips Inc. | -632.18 Million JPY | -318.233% |
| K Pharma,Inc. | 260.33 Million JPY | 1115.634% |
| Takara Bio Inc. | 1.48 Billion JPY | 278.649% |
| ReproCELL Incorporated | -31.41 Million JPY | -8316.362% |
| PhoenixBio Co., Ltd. | 26.37 Million JPY | 10123.504% |
| StemCell Institute Inc. | 310.98 Million JPY | 950.213% |
| Japan Tissue Engineering Co., Ltd. | 143.16 Million JPY | 1946.769% |
| CellSeed Inc. | -846.53 Million JPY | -212.332% |